Immedica expands into the U.S., establishes Chicago-based commercial business
Stockholm, September 9, 2024 – Immedica Pharma AB, a global pharmaceutical company dedicated to addressing rare and severe diseases, is excited to announce the establishment of its U.S. commercial business, Immedica Pharma US Inc. headquartered in Chicago.
With a strong presence in Europe and the Middle East, Immedica’s entry into the U.S. market underscores its ambition to become a global leader in the rare disease sector. The new entity will focus on introducing innovative therapies to the U.S. market, aiming to expand the range of available treatment options.
“This expansion into the U.S. is a pivotal moment for Immedica as we continue our mission to deliver life-changing therapies to people living with rare diseases,” said Anders Edvell, CEO of Immedica Pharma. “Our presence in the U.S will allow us to better serve the needs of patients in North America and marks a pivotal step in Immedica’s ongoing commitment to serving unmet medical needs on a global scale”.
About Immedica
Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica’s capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica’s therapeutic areas are within genetic & metabolic diseases, hematology & oncology and specialty care.
Immedica was founded in 2018 by the investment company Impilo and Buy-in-Management. Today Immedica employs more than 120 people across Europe, the Middle East and the US.
For more information visit www.immedica.com
Immedica contact:
Linda Holmström
Head of Communication
linda.holmstrom@immedica.com
Immedica Pharma AB
Solnavägen 3H
SE-113 63 Stockholm
